Literature DB >> 8314500

Low dose interferon alfa-2b for chronic hepatitis B in Asian countries.

E Mauracher1.   

Abstract

In a study of low dose interferon alfa-2b in 587 patients expected to show a good response to treatment, 76-87% patients in different countries had alanine amino-transferase activities returned to normal after four months' treatment, 49-72% were negative for hepatitis B virus (HBV)-DNA, 51-66% were negative for hepatitis B e antigen (HBeAg), and 44-62% were anti-HBe positive. These effects were maintained after nine to 12 months' follow up. Side effects were mild, but led to discontinuation of treatment in 12 patients.

Entities:  

Mesh：

Substances：

Year:  1993        PMID： 8314500      PMCID： PMC1374023          DOI： 10.1136/gut.34.2_suppl.s99

Source DB:  PubMed          Journal:  Gut        ISSN： 0017-5749            Impact factor:   23.059


  8 in total

1.  Factors influencing response to interferon in chronic hepatitis B: implications for Asian and western populations.

Authors:  R P Perrillo
Journal:  Hepatology       Date:  1990-12       Impact factor: 17.425

2.  Treatment of chronic viral hepatitis.

Authors:  S Sherlock
Journal:  J Hepatol       Date:  1988-02       Impact factor: 25.083

3.  Randomised controlled trial of interferon alfa 2A (rbe) (Roferon-A) for the treatment of chronic hepatitis B virus (HBV) infection: factors that influence response.

Authors:  M G Brook; J A McDonald; P Karayiannis; L Caruso; G Forster; J R Harris; H C Thomas
Journal:  Gut       Date:  1989-08       Impact factor: 23.059

4.  Randomized, controlled trial of recombinant human alpha-interferon in patients with chronic hepatitis B.

Authors:  J H Hoofnagle; M Peters; K D Mullen; D B Jones; V Rustgi; A Di Bisceglie; C Hallahan; Y Park; C Meschievitz; E A Jones
Journal:  Gastroenterology       Date:  1988-11       Impact factor: 22.682

5.  Pilot study of recombinant human alpha-interferon for chronic type B hepatitis.

Authors:  J S Dooley; G L Davis; M Peters; J G Waggoner; Z Goodman; J H Hoofnagle
Journal:  Gastroenterology       Date:  1986-01       Impact factor: 22.682

6.  Prednisone withdrawal followed by recombinant alpha interferon in the treatment of chronic type B hepatitis. A randomized, controlled trial.

Authors:  R P Perrillo; F G Regenstein; M G Peters; K DeSchryver-Kecskemeti; C J Bodicky; C R Campbell; M C Kuhns
Journal:  Ann Intern Med       Date:  1988-07-15       Impact factor: 25.391

7.  Long-term follow-up in a randomised controlled trial of recombinant alpha 2-interferon in Chinese patients with chronic hepatitis B infection.

Authors:  A S Lok; C L Lai; P C Wu; E K Leung
Journal:  Lancet       Date:  1988-08-06       Impact factor: 79.321

8.  Which patients with chronic hepatitis B virus infection will respond to alpha-interferon therapy? A statistical analysis of predictive factors.

Authors:  M G Brook; P Karayiannis; H C Thomas
Journal:  Hepatology       Date:  1989-11       Impact factor: 17.425
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.